Combined epidermal growth factor receptor and beclin1 autophagic protein expression analysis identifies different clinical presentations, responses to chemo- and radiotherapy, and prognosis in glioblastoma

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Tini, Paolo ^a,b,c   Belmonte, Giuseppe ^a,c   Toscano, Marzia ^a,c   Miracco, Clelia ^a,c   Palumbo, Silvia ^d   Pastina, Pierpaolo ^a,c   Battaglia, Giuseppe ^a,c   Nardone, Valerio ^a,c   Butorano, Marie Aimée Gloria Munezero ^c   Masucci, Armando ^e   Cerase, Alfonso ^b   Pirtoli, Luigi ^a,b,c  

^a ISTITUTO TOSCANO TUMORI   (Italy)

^b UNIVERSITY HOSPITAL OF SIENA   (Italy)

^c UNIVERSITY OF SIENA   (Italy)

^d UNIVERSITY OF PAVIA   (Italy)

^e S G MOSCATI HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BECLIN 1; EPIDERMAL GROWTH FACTOR RECEPTOR; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE; APOPTOSIS REGULATORY PROTEIN; BECN1 PROTEIN, HUMAN; EGFR PROTEIN, HUMAN; MEMBRANE PROTEIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; AUTOPHAGY; CANCER PROGNOSIS; CHEMORADIOTHERAPY; GLIOBLASTOMA; HUMAN; KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; MOLECULARLY TARGETED THERAPY; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; BRAIN NEOPLASMS; GENE EXPRESSION REGULATION; METABOLISM; MIDDLE AGED; PROGNOSIS; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS REGULATORY PROTEINS; AUTOPHAGY; BIOMARKERS, TUMOR; BRAIN NEOPLASMS; CHEMORADIOTHERAPY; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; MEMBRANE PROTEINS; MIDDLE AGED; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 84925308653     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/208076     Document Type: Article

References (46)

1. National Comprehensive Cancer Network, National Comprehensive Cancer Network Guidelines, 2014.
2. W. J. Curran Jr., C. B. Scott, J. Horton et al., "Recursive partitioning analysis of prognostic factors in three radiation therapy oncology group malignant glioma trials," Journal of the National Cancer Institute, vol. 85, no. 9, pp. 704-710, 1993.
3. R. G. W. Verhaak, K. A. Hoadley, E. Purdom et al., "Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1," Cancer Cell, vol. 17, no. 1, pp. 98-110, 2010.
4. C. W. Brennan, R. G. Verhaak, A. McKenna et al., "The somatic genomic landscape of glioblastoma," Cell, vol. 155, no. 2, pp. 462-477, 2013.
5. M. Preusser, S. de Ribaupierre, A. Wöhrer et al., "Current concepts and management of glioblastoma," Annals of Neurology, vol. 70, no. 1, pp. 9-21, 2011.
6. A. Chakravarti, A. Dicker, and M. Mehta, "The contribution of epidermal growth factor receptor (EGFR) signaling pathway to radioresistance in human gliomas: a review of preclinical and correlative clinical data," International Journal of Radiation Oncology Biology Physics, vol. 58, no. 3, pp. 927-931, 2004.
7. R. Shen, Q. Mo, N. Schultz et al., "Integrative subtype discovery in glioblastoma using iCluster," PLoS ONE, vol. 7, no. 4, Article ID e35236, 2012.
8. J. Yan, H. Yang, G. Wang et al., "Autophagy augmentedby troglitazone is independent of EGFR transactivation and correlated with AMP-activated protein kinase signaling," Autophagy, vol. 6, no. 1, pp. 67-73, 2010.
9. B. Levine and D. J. Klionsky, "Development by self-digestion: molecular mechanisms and biological functions of autophagy," Developmental Cell, vol. 6, no. 4, pp. 463-477, 2004.
10. Z. J. Yang, C. E. Chee, S. Huang, and F. A. Sinicrope, "The role of autophagy in cancer: therapeutic implications," Molecular Cancer Therapeutics, vol. 10, no. 9, pp. 1533-1541, 2011.
11. D. C. Rubinsztein, P. Codogno, and B. Levine, "Autophagy modulation as a potential therapeutic target for diverse diseases," Nature Reviews Drug Discovery, vol. 11, no. 9, pp. 709-730, 2012.
12. J. N. Sarkaria, E. Galanis, W. Wu et al., "North central cancer treatment group Phase I trial N057K of everolimus (RAD001) and temozolomide in combination with radiation therapy in patients with newly diagnosed glioblastoma multiforme," International Journal of Radiation Oncology Biology Physics, vol. 81, no. 2, pp. 468-475, 2011.
13. S. Palumbo, L. Pirtoli, P. Tini et al., "Different involvement of autophagy in human malignant glioma cell lines undergoing irradiation and temozolomide combined treatments," Journal of Cellular Biochemistry, vol. 113, no. 7, pp. 2308-2318, 2012.
14. T. Kanzawa, I. M. Germano, T. Komata, H. Ito, Y. Kondo, and S. Kondo, "Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells," Cell Death and Differentiation, vol. 11, no. 4, pp. 448-457, 2004.
15. W. Zhuang, Z. Qin, and Z. Liang, "The role of autophagy in sensitizing malignant glioma cells to radiation therapy," Acta Biochimica et Biophysica Sinica, vol. 41, no. 5, pp. 341-351, 2009.
16. V. Nikoletopoulou, M. Markaki, K. Palikaras, and N. Tavernarakis, "Crosstalk between apoptosis, necrosis and autophagy," Biochimica et Biophysica Acta, vol. 1833, no. 12, pp. 3448-3459, 2013.
17. S. Palumbo and S. Comincini, "Autophagy and ionizing radiation in tumors: the "survive or not survive" dilemma," Journal of Cellular Physiology, vol. 228, no. 1, pp. 1-8, 2013.
18. R. Kang, H. J. Zeh, M. T. Lotze, and D. Tang, "The Beclin 1 network regulates autophagy and apoptosis," Cell Death and Differentiation, vol. 18, no. 4, pp. 571-580, 2011.
19. Y. Wei, Z. Zou, N. Becker et al., "XEGFR-mediated beclin 1 phosphorylation in autophagy suppression, tumor progression, and tumor chemoresistance," Cell, vol. 154, no. 6, pp. 1269-1284, 2013.
20. M. Lund-Johansen, R. Bjerkvig, P. A. Humphrey, S. H. Bigner, D. D. Bigner, and O.-D. Laerum, "Effect of epidermal growth factor on glioma cell growth, migration, and invasion in vitro," Cancer Research, vol. 50, no. 18, pp. 6039-6044, 1990.
21. F. G. Barker II, M. L. Simmons, S. M. Chang et al., "EGFR overexpression and radiation response in glioblastomamultiforme," International Journal of Radiation Oncology Biology Physics, vol. 51, no. 2, pp. 410-418, 2001.
22. C. Miracco, E. Cosci, G. Oliveri et al., "Protein and mRNA expression of autophagy gene Beclin 1 in human brain tumours," International Journal of Oncology, vol. 30, no. 2, pp. 429-436, 2007.
23. X. Huang, H. M. Bai, L. Chen, B. Li, and Y. C. Lu, "Reduced expression of LC3B-II and Beclin 1 in glioblastoma multiforme indicates a down-regulated autophagic capacity that relates to the progression of astrocytic tumors," Journal of Clinical Neuroscience, vol. 17, no. 12, pp. 1515-1519, 2010.
24. L. Pirtoli, G. Cevenini, P. Tini et al., "The prognostic role of Beclin 1 protein expression in high-grade gliomas," Autophagy, vol. 5, no. 7, pp. 930-936, 2009.
25. S. Palumbo, P. Tini, M. Toscano et al., "Combined EGFR and autophagy modulation impairs cell migration and enhances radiosensitivity in human glioblastoma cells," Journal of Cellular Physiology, vol. 229, no. 11, pp. 1863-1873, 2014.
26. D. N. Louis, H. Ohgaki, O. D. Wiestler, and W. K. Cavenee, WHO Classification of Tumours of the Central Nervous System, IARC, Lyon, France, 2007.
27. L. Pirtoli, G. Rubino, S. Marsili et al., "Three-dimensional conformal radiotherapy, temozolomide chemotherapy, and highdose fractionated stereotactic boost in a protocol-driven, postoperative treatment schedule for high-grade gliomas," Tumori, vol. 95, no. 3, pp. 329-337, 2009.
28. ICRU, "International Commission on Radiation Units and Measurements. Prescribing, recording, and reporting photon beam therapy, Supplement to ICRU Report No. 50," ICRU Report 62, ICRU, Bethesda, Md, USA, 1999.
29. "Prognostic factors for high-grade malignant glioma : development of a prognostic index. A Report of the Medical Research Council Brain Tumour Working Party," Journal of Neuro-Oncology, vol. 9, no. 1, pp. 47-55, 1990.
30. D. R. Macdonald, T. L. Cascino, S. C. Schold Jr., and J. G. Cairncross, "Response criteria for phase II studies of supratentorial malignant glioma," Journal of Clinical Oncology, vol. 8, no. 7, pp. 1277-1280, 1990.
31. P. Y. Wen, D. R. Macdonald, D. A. Reardon et al., "Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group," Journal of Clinical Oncology, vol. 28, no. 11, pp. 1963-1972, 2010.
32. M. E. Hegi, A.-C. Diserens, T. Gorlia et al., "MGMT gene silencing and benefit from temozolomide in glioblastoma," The New England Journal of Medicine, vol. 352, no. 10, pp. 997-1003, 2005.
33. R. Stupp, M. E. Hegi, B. Neyns et al., "Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma," Journal of Clinical Oncology, vol. 28, no. 16, pp. 2712-2718, 2010.
34. S. M. Magrini, U. Ricardi, R. Santoni et al., "Patterns of practice and survival in a retrospective analysis of 1722 adult astrocytoma patients treated between 1985 and 2001 in 12 Italian radiation oncology centers," International Journal of Radiation Oncology Biology Physics, vol. 65, no. 3, pp. 788-799, 2006.
35. C. Hartmann, B. Hentschel, W. Wick et al., "Patients with IDH1wild type anaplastic astrocytomas exhibitworse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas," Acta Neuropathologica, vol. 120, no. 6, pp. 707-718, 2010.
36. M. Nagane, F. Coufal, H. Lin, O. Bögler, W. K. Cavenee, and H.-J. S. Huang, "Acommonmutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis," Cancer Research, vol. 56, no. 21, pp. 5079-5086, 1996.
37. B. Li, M. Yuan, I. A. Kim, C. M. Chang, E. J. Bernhard, and H. K. G. Shu, "Mutant epidermal growth factor receptor displays increased signaling through the phosphatidylinositol- 3 kinase/AKT pathway and promotes radioresistance in cells of astrocytic origin," Oncogene, vol. 23, no. 26, pp. 4594-4602, 2004.
38. T. E. van Meter, W. C. Broaddus, H. K. Rooprai, G. J. Pilkington, and H. L. Fillmore, "Inductionofmembrane-type-1matrixmetalloproteinase by epidermal growth factor-mediated signaling in gliomas," Neuro-Oncology, vol. 6, no. 3, pp. 188-199, 2004.
39. K. J. Hatanpaa, S. Burma, D. Zhao, and A. A. Habib, "Epidermal growth factor receptor in glioma: signal transduction, neuropathology, imaging, and radioresistance," Neoplasia, vol. 12, no. 9, pp. 675-684, 2010.
40. A. Chakravarti, A. Chakladar, M. A. Delaney, D. E. Latham, and J. S. Loeffler, "The epidermal growth factor receptor pathway mediates resistance to sequential administration of radiation and chemotherapy in primary human glioblastoma cells in a RAS-dependent manner," Cancer Research, vol. 62, no. 15, pp. 4307-4315, 2002.
41. B. Kalman, E. Szep, F. Garzuly, and D. E. Post, "Epidermal growth factor receptor as a therapeutic target in glioblastoma," Neuro Molecular Medicine, vol. 15, no. 2, pp. 420-434, 2013.
42. Z. Yang and D. J. Klionsky, "Eaten alive: a history of macroautophagy," Nature Cell Biology, vol. 12, no. 9, pp. 814-822, 2010.
43. G. Maheshwari, A. Wells, L.G. Griffith, and D.A. Lauffenburger, "Biophysical integration of effects of epidermal growth factor and fibronectin on fibroblast migration," Biophysical Journal, vol. 76, no. 5, pp. 2814-2823, 1999.
44. A. Wells, "Tumor Invasion: role of growth factor-induced cell motility," Advances in Cancer Research, vol. 78, pp. 31-101, 1999.
45. A. Wells, J. Kassis, J. Solava, T. Turner, and D. A. Lauffenburger, "Growth factor-induced cell motility in tumor invasion," Acta Oncologica, vol. 41, no. 2, pp. 124-130, 2002.
46. M. Dong, X.-B. Wan, Z. Y. Yuan et al., "Low expression of Beclin 1 and elevated expression of HIF-1α refine distant metastasis risk and predict poor prognosis of ER-positive, HER2-negative breast cancer," Medical Oncology, vol. 30, no. 1, article 355, 2013.